Anti-fibrotic Coatings for Rapidly Exchangeable Bioprosthetic Heart Valve

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$1,616,038.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44HL072547-02A2
Award Id:
65775
Agency Tracking Number:
HL072547
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
VALVEXCHANGE, INC., c/o Ivan Vesely, AURORA, CO, 80045
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
780997065
Principal Investigator:
() -
Business Contact:
() -
vesely@valvexchange.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Each year, over 100,000 patients in the United States need to have their diseased heart valves replaced with artificial devices. Although bioprostheses, valves made from animal tissues, are considered ideal for most pat ients, they wear out in about 15 years. They are thus used primarily in the elderly patient who is not expected to outlive the valve. Younger patients receive mechanical valves that are more durable, but require chronic administration of blood thinners. Th is makes participation in most sports impossible and exposes the patient to increased risk for fatal bleeds and strokes. ValveXchange, Inc. ( VXI ) is a medical device company developing a two-part heart valve consisting of a surgically implanted base and an exchangeable bioprosthetic tissue leaflet set. The VXI device is a lifetime tissue valve replacement system that does not require anticoagulation. During the first surgery, the docking station is first sewn in place and the leaflets are snapped in. This allows the surgeon to place sutures more conveniently, without risk of damaging the leaflet core. As the leaflet set begins to show signs of wear it can be exchanged rapidly, using a minimally invasive surgical or percutaneous procedure. Rapid, minimally invasive leaflet exchange dramatically reduces surgical time and eliminates the need the technically demanding and potentially dangerous re-excision of the initial prosthetic valve. As the leaflet set is exchanged, the docking station remains permanently i n place so there is no disruption of the sensitive tissue of the aortic root; a vital part of the conduction system of the heart and the origin of the coronary arteries. VXI has successfully completed two Phase I projects. In the first, VXI develop ed prototype exchangeable valves and demonstrated their technical feasibility in an animal model by exchanging a valve in 23 seconds. In the second, VXI investigated the ability of anti-adhesion coatings to abate fibrotic overgrowth in the hyper-fibrotic s heep model. In this Phase II application we propose to implement our novel anti-adhesion coatings in a chronic sheep model and investigate the long-term host response of the rapidly exchangeable valve. We will fabricate 8 valves each from bare coba lt-chrome, cobalt-chrome treated with a stearate coating, and from pyrolitic carbon. Both stearate and pyrolitic carbon have been shown to repel fibrotic overgrowth in the Phase I study. A control group will make use of the gold standard Edwards pericard ial valve. After 3 and 5 months of implantation, the leaflet sets will be exchanged using an open surgical procedure in which the reduced time on cardiac bypass will be documented, and the degree of fibrotic overgrowth measured. Detailed measurements of fi brotic overgrowth and incidence of thromboembolism will be examined at necropsy. This revised resubmission now includes more specific criteria upon which to base a redesign of the valve and the anti-fibrotic coatings. Each year, over 100,000 patients in th e United States need to have their diseased heart valves replaced with artificial devices. Although artificial heart valves made from materials of animal origin are considered ideal for most patients, they wear out in about 15 years. They are thus used pri marily in the elderly patient who is not expected to outlive the valve. Younger patients receive mechanical valves, made from metals and graphite-like materials. Although these types of valves will last the life of the patient, they require the patient to be on blood thinners. This makes participation in most sports impossible and exposes the patient to increased risk for fatal bleeds and strokes. ValveXchange, Inc. ( VXI ) is a medical device company developing a two-part heart valve consisting of a surgic ally implanted base and an exchangeable animal tissue-based leaflet set. The VXI device is a lifetime tissue valve replacement system that does not require

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government